International Organization of MS Nurses
Written by Administrator2
- HIGHLIGHTS FROM THE 7th ANNUAL LINDA MORGANTE MS NURSE LEADERSHIP PROGRAM
Early and advanced career nurses who practice in the field of MS can now access program highlights from the 7th Annual Linda Morgante MS Nurse Leadership Program held on May 26-27, 2015 in Indianapolis, IN. Topics covered by 12 thought leaders at the 2-day program are summarized within the newsletter and relate to: the pathophysiology of MS, diagnostic and assessment approaches, maintaining/improving patient medication adherence, and symptom management. Learn more.
CEU: A maximum of 2.00 contact hours may be earned for successful completion of this activity.
Released Date: September 25, 2015 Expires On: September 26, 2016
- NEW CHALLENGES FACING MULTIPLE SCLEROSIS NURSES
This activity is intended for nurses and nurse practitioners engaged in the care of patients with multiple sclerosis (MS) and related disorders.
The goal of this activity is to provide an overview of MS pathology, symptomatology, and the risks and benefits of currently available disease-modifying therapies and other therapeutic approaches. Learn more.
Credits Available: Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology
CE Released: 05/29/2015 ; Valid for credit through 05/29/2016
- COUNSELING POINTS: WINTER 2016 Volume 11, Number 1
The Role of the MS Nurse in Relapse Assessment and Management
- MOVING FORWARD:
Adherence to Therapy & the Role of Nursing in MS
- MS BLUEPRINT, A UNIQUE NEW TOOL FOR THE MS COMMUNITY, HAS LAUNCHED!
The International Organization of Multiple Sclerosis Nurses (IOMSN) has partnered with Biogen Idec to launch MS Blueprint™, a program to encourage those impacted by MS to set goals, create personalized activity plans called MS Blueprints, and take small steps to attain a more positive life. Learn more
- MS COALITION: The Use of Disease-Modifying Therapies in MS
The member organizations of the Multiple Sclerosis Coalition have collaborated to summarize the current evidence about disease modification in multiple sclerosis (MS) and to provide support for broad access to U.S. Food and Drug Administration (FDA)-approved MS disease-modifying therapies for people.
- 2nd Congress of the European Academy of Neurology (EAN)
Copenhagen, Denmark - May 28-31, 2016
3rd Congress of the European Academy of Neurology (EAN)
Amsterdam, The Netherlands - June 24-27, 2017